ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,928Medicare Part D Prescriptions Filled, Including Refills

Rank: 536 out of 5176

$1.57M Total Retail Price of All Prescriptions

Rank: 99 out of 5176

420 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
87% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 10,524 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

61% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$143 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
EVISTA 1,089 1,058 10 1 65
AMLODIPINE BESYLATE 585 562 2 2
PRAVASTATIN SODIUM 311 285 3 23
CRESTOR 304 295 4 15
ATORVASTATIN CALCIUM 304 303 4 9
DIOVAN 249 245 6 19
SINGULAIR 240 227 7 62
SIMVASTATIN 219 205 8 1
MELOXICAM 208 205 9 53
LOSARTAN POTASSIUM 203 194 10 14
OMEPRAZOLE 196 179 11 3
ONGLYZA 191 177 12 153
NEXIUM 188 183 13 16
METOPROLOL SUCCINATE 185 185 14 11
JANUVIA 170 169 15 25
DIOVAN HCT 164 164 16 39
ALENDRONATE SODIUM 156 153 17 18
LIPITOR 154 149 18 51
TAMSULOSIN HCL 154 148 18 20
AMMONIUM LACTATE 153 150 20 91
ATENOLOL 148 131 21 12
CELEBREX 141 136 22 80
METFORMIN HCL 137 133 23 7
CYMBALTA 133 133 24 90
PLAVIX 129 123 25 29
CLOPIDOGREL 127 117 26 26
ACTOS 125 123 27 85
ALLOPURINOL 125 125 27 41
LOSARTAN-HYDROCHLOROTHIAZIDE 122 113 29 35
KOMBIGLYZE XR 115 105 30 291
PATADAY 114 106 31 220
FEXOFENADINE HCL 112 112 32 358
BYSTOLIC 102 102 33 96
FINASTERIDE 100 95 34 69
BENICAR 99 99 35 100
PROLIA 94 93 36 448
PROPRANOLOL HCL 89 89 37 199
LIDODERM 88 85 38 59
AMLODIPINE BESYLATE-BENAZEPRIL 84 82 39 55
PROAIR HFA 80 80 40 60
FLUTICASONE PROPIONATE 77 72 41 38
DOXAZOSIN MESYLATE 77 72 41 103
DONEPEZIL HCL 72 72 43 28
FORTEO 70 70 44 264
MONTELUKAST SODIUM 68 67 45 123
MICARDIS 67 67 46 154
MOMETASONE FUROATE 66 66 47 251
LEVOTHYROXINE SODIUM 63 55 48 4
GLIPIZIDE XL 62 60 49 83
POTASSIUM CHLORIDE 59 59 50 34
AVODART 56 56 51 107
TEKTURNA 54 54 52 255
GLIMEPIRIDE 52 52 53 37
EXFORGE 52 52 53 126
TRICOR 52 52 53 148
NIASPAN 51 51 56 175
LOVASTATIN 50 50 57 46
BENICAR HCT 50 50 57 110
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 19, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.